m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG02823)
Name |
Trilaciclib
|
||||
---|---|---|---|---|---|
Synonyms |
G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra
Click to Show/Hide
|
||||
Status |
Approved
|
||||
Structure |
|
||||
Formula |
C24H30N8O
|
||||
InChI |
1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)
|
||||
InChIKey |
PDGKHKMBHVFCMG-UHFFFAOYSA-N
|
||||
PubChem CID | |||||
TTD Drug ID |
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Cyclin-dependent kinase 4 (CDK4)
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Trilaciclib. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of Trilaciclib through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [2] | ||
Protein virilizer homolog (VIRMA)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Trilaciclib. The Protein virilizer homolog (VIRMA) has potential in affecting the response of Trilaciclib through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [1], [2] | ||
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Cyclin-dependent kinase 4 (CDK4) is a therapeutic target for Trilaciclib. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of Trilaciclib through regulating the expression of Cyclin-dependent kinase 4 (CDK4). | [2], [3] | ||
Cyclin-dependent kinase 6 (CDK6)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response | ||||
Response Summary | Cyclin-dependent kinase 6 (CDK6) is a therapeutic target for Trilaciclib. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Trilaciclib through regulating the expression of Cyclin-dependent kinase 6 (CDK6). | [2], [4] | ||
References